Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

employee- and office-related expenses.

-- In the fourth quarter ended December 31, 2007, Sunesis recorded a $0.3

million additional restructuring charge as a result of the company's

reorganization and reduction in force in the third quarter of 2007.

For the year ended December 31, 2007, an aggregate of $1.6 million in

restructuring charges was recorded. Cash restructuring costs accounted

for approximately $1.1 million of the total $1.6 million restructuring

charge for the year.

-- Sunesis reported a net loss of $8.8 million for the fourth quarter of

2007 and of $38.8 million for the twelve-month period ended December

31, 2007, compared to a reported net loss of $9.0 million and $31.2

million, respectively, for the three-month and twelve-month periods

ended December 31, 2006.

-- In 2008, Sunesis expects net cash used in operating activities of

approximately $30 million - $35 million in the absence of any new

collaborations, compared to $34.5 million in 2007. A decrease in net

cash used in operating activities is anticipated primarily due to the

reorganization effected in August of last year, partially offset by

increased costs associated with clinical trial and other development

activities for SNS-595, SNS-032 and SNS-314.

Conference Call Information

Sunesis' management will host a conference call to review the results of the fourth quarter and the 2007 fiscal year today at 10:30 a.m. EDT. Individual and institutional investors can access the call via 877-604-9668 (U.S. and Canada) or 719-325-4904 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website severa
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 21, 2014 The North American crystal ... North America with analysis and forecast of revenue. This ... is expected to reach $623.6 million by 2018, at ... Browse through the TOC of the North American crystal ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... A decade of helping scientists and clinicians understand life one cell ... ... time, HAYWARD, Calif., Feb. 6 This year ... technologies directly to the lab benches of thousands of,scientists and clinicians ...
... Feb. 5 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ... Annual,BIO CEO and Investor Conference on Tuesday, February 12, ... is being held at the Waldorf-Astoria,Hotel in New York., ... of Anadys,Pharmaceuticals, Inc., will present an overview of Anadys ...
... ... Expertise, OMAHA, Neb., Feb. ... has appointed David P.,Pauluzzi to its Board of Directors. Mr. Pauluzzi ... equity firm,specializing in the healthcare sector., Prior to his current ...
Cached Biology Technology:Guava Technologies Celebrates Tenth Anniversary 2Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference 2Transgenomic Appoints David Pauluzzi to Board of Directors 2Transgenomic Appoints David Pauluzzi to Board of Directors 3
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... a long time that only 2% -- 3% of human ... genomes -- often referred to as junk DNA -- consists ... into DNA, and then reinserted into a new spot in ... these retroelements. Retroviruses can insinuate themselves into the host's DNA ...
... presented at the CIC bioGUNE hold at ... DNA chip concerning diagnosis and prognosis of ... normal, steatosis and NASH predisposed subjects. , ... of the liver of unknown etiology, characterized ...
... pioneering research into diseases such as Creutzfeld-Jakob Disease (CJD) and ... to a £300,000 grant from the Medical Research Council. , ... probable variant CJD (vCJD) in the UK. This is the ... with prions that is also responsible for the epidemic of ...
Cached Biology News:Chimp genome reveals a retroviral invasion 2Chimp genome reveals a retroviral invasion 3Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis 2
ANTI DEOXY CORTICO...
... Automatic High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples ... analysis and record keeping. Bar code reading capability with optional scanner. RS-232 ... ... ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
sodium channel, nonvoltage-gated 1 alpha,...
Biology Products: